

Disclaimer: This document is an English translation of the original document in Japanese and has been prepared solely for reference purposes. In the event of any discrepancy between this English translation and the original in Japanese, the original shall prevail in all respects.



May 8, 2025

To whom it may concern:

Company name	KISSEI PHARMACEUTICAL CO., LTD.
Representative	Mutsuo Kanzawa, Chairman and CEO (Stock code 4547; Prime Market, Tokyo Stock Exchange)
Contact	Takahide Kitahara, Managing Director, Department Manager of Corporate Finance and Management Department, CFO (Telephone +81-263-25-9081)

Notice Concerning the Results of the Acquisition of Treasury Shares, Through Off-Auction Treasury Share Repurchase Trading System(ToSTNeT-3), the Completion of Acquisition of Treasury shares and the Cancellation of Treasury Shares

KISSEI PHARMACEUTICAL CO., LTD. (the “Company”) announces that it has completed purchases as follows for the acquisition of treasury as announced on May 7, 2025. As a result, the acquisition of treasury shares based on the resolution of the Board of Directors meeting held on May 7, 2025 has now ended.

The Company also announces that the number of shares to be cancelled has been finalized pursuant to Article 178 of the Companies Act.

1. Reasons for acquisition and cancellation of treasury shares
To execute a flexible capital policy in response to changes in the business environment , while improving capital efficiency and enhancing shareholder returns.
2. Details of the acquisition
 - (1) Type of shares acquired: Common shares of the Company
 - (2) Total number of shares acquired: 1,369,200 shares
(Percentage of total number of issued shares (excluding treasury shares): 3.20%)
 - (3) Total acquisition cost: 5,216,652,000 yen
 - (4) Date of acquisition: May 8, 2025
 - (5) Method of acquisition: Purchase Through Off-Auction Own Repurchase Trading System(ToSTNeT-3) of the Tokyo Stock Exchange
3. Details of the cancellation
 - (1) Type of shares to be cancelled: Common shares of the Company
 - (2) Total number of shares to be cancelled: 1,369,200 shares
(Percentage of total number of issued shares before the cancellation: 2.86%)
 - (3) Total number of issued shares after the cancellation: 46,541,985 shares
 - (4) Scheduled date of cancellation: June 27, 2025

(Reference)

1. Details of the resolution on the acquisition of treasury shares at the Board of Directors meeting held on May 7, 2025
 - (1) Type of shares to be acquired: Common shares of the Company
 - (2) Total number of shares to be acquired: Up to 1,400,000 shares
(Percentage of total number of issued shares (excluding treasury shares): 3.27%)
 - (3) Total acquisition cost: 5,334,000,000 yen (maximum)
2. Details of the resolution on the cancellation of treasury shares at the Board of Directors meeting held on May 7, 2025
 - (1) Type of shares to be cancelled: Common shares of the Company
 - (2) Total number of shares to be cancelled: All treasury shares acquired through item 1 above
 - (3) Scheduled date of cancellation: June 27, 2025

-End-